Abstract
Central nervous system diseases commonly occur with the destruction of the blood-brain barrier. As a primary cause of morbidity and mortality, stroke remains unpredictable and lacks cellular biomarkers that accurately quantify its occurrence and development. Here, we identify NeuN+/CD45−/DAPI+ phenotype nonblood cells in the peripheral blood of mice subjected to middle cerebral artery occlusion (MCAO) and stroke patients. Since NeuN is a specific marker of neural cells, we term these newly identified cells as circulating neural cells (CNCs). We find that the enumeration of CNCs in the blood is significantly associated with the severity of brain damage in MCAO mice (p < 0.05). Meanwhile, the number of CNCs is significantly higher in stroke patients than in negative subjects (p < 0.0001). These findings suggest that the amount of CNCs in circulation may serve as a clinical indicator for the real-time prognosis and progression monitor of the occurrence and development of ischemic stroke and other nervous system disease.
Highlights
Central nervous system diseases, including brain injury, stroke [1, 2], brain tumors [3, 4], neurodegenerative diseases [5], and cognitive dysfunction associated with aging [6, 7], commonly occur via the destruction of the blood-brain barrier (BBB)
Our results indicate that circulating neural cells (CNCs) variation in the blood reflects the degree of ischemic brain injury and can serve as a potential marker of brain damage
This study indicated that neural cells spread from the brain-injury area to the peripheral blood during BBB breakdown
Summary
Central nervous system diseases, including brain injury, stroke [1, 2], brain tumors [3, 4], neurodegenerative diseases [5], and cognitive dysfunction associated with aging [6, 7], commonly occur via the destruction of the blood-brain barrier (BBB). For example, BBB breakdown is observed in the venous microvessels and distal capillaries at. Eighty-six percent of all cases of stroke are ischemic in nature [10]. As a primary cause of morbidity and mortality, stroke lacks effective cellular biomarkers that accurately quantify its occurrence and development. Biomarkers that signal and Research qualify the risk of initial or recurrent acute stroke are important [13]. Circulating cells secreted by organs into the circulatory system act as molecular biomarkers (e.g., proteins, microRNAs, and cell-free nucleic acids) that provide critical information regarding health and illness [14]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
